Successful Treatment of Crizotinib-Associated Severe Hepatotoxicity in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Soonchunhyang Medical Science
;
: 35-38, 2014.
Article
in English
| WPRIM
| ID: wpr-107299
ABSTRACT
Crizotinib-associated severe hepatotoxicity has been rarely reported and experts recommended stopping crizotinib treatment in patients with grade 3/4 transaminase elevation. We experienced a case of anaplastic lymphoma kinase-positive non-small cell lung cancer occurring as a result of severe hepatotoxicity due to crizotinib-associated hepatitis, accompanied by the reactivation of chronic hepatitis B, which was reversed with dose reduction and anti-viral therapy. Our case highlights the possibility that crizotinib might induce hepatitis and this might be associated with the underlying presence of chronic hepatitis B. In addition, crizotinib could be continued with reduced unless there are any other therapeutic options.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Hepatitis B, Chronic
/
Hepatitis
/
Lymphoma
Limits:
Humans
Language:
English
Journal:
Soonchunhyang Medical Science
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS